Over-the-counter antihistamines and a prescription anti-inflammatory drug both have a small benefit in reducing long COVID ...

Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai Tianqing Pharmaceutical ...

Having higher vs. lower levels of vitamin A was linked to better measures of FEV1 and forced vital capacity in children and ...

AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & ...

The American Lung Association is announcing a new initiative to help people living with chronic obstructive pulmonary disease (COPD) better manage symptoms and improve quality of life. More than 16 ...

The introduction of biologic therapies for severe asthma has transformed clinical practice. Among these agents, benralizumab ...

In AstraZeneca’s third trip to Asia this year, the pharma secured ex-China rights to a dual inhibitor of PDE3 and PDE4, which in a Phase 2b study significantly improved lung function and lowered ...

This evaluation examines the formula, manufacturing standards, guarantee terms, and common skeptical concerns to give you a ...

It’s a simple question that physicians usually do not ask their patients: “When was your last drink?” “If the patient says yesterday, you know the patient isn’t a casual drinker,” said Joe G. Zein, MD ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The 2026 GOLD report newly highlights disease activity ...

AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...